NIAID drops Lilly antibody from ACTIV-3 COVID-19 trialEli Lilly says no more patients will be treated with its COVID-19 therapy bamlanivimab in a trial run Share XNIAID drops Lilly antibody from ACTIV-3 COVID-19 trialhttps://pharmaphorum.com/news/niaid-drops-lilly-antibody-from-activ-3-covid-19-trial/
Lilly to buy private biotech Disarm Therapeutics for up to $1.36bnEli Lilly is to buy the private biotech Disarm Therapeutics, which is working on a new class of Share XLilly to buy private biotech Disarm Therapeutics for up to $1.36bnhttps://pharmaphorum.com/news/lilly-to-buy-private-biotech-disarm-therapeutics-for-up-to-1-36bn/
Lilly pauses COVID-19 antibody trial after factory hits trouble with FDAEli Lilly has put a clinical trial of its COVID-19 antibody therapy on hold after FDA inspectors found Share XLilly pauses COVID-19 antibody trial after factory hits trouble with FDAhttps://pharmaphorum.com/news/lilly-pauses-covid-19-antibody-trial-after-factory-hits-trouble-with-fda/
Ibrance trial failure dashes Pfizer’s growth hopes for the drugPfizer already makes big revenues from its breast cancer drug Ibrance, but a late-stage trial failure has set Share XIbrance trial failure dashes Pfizer’s growth hopes for the drughttps://pharmaphorum.com/news/ibrance-trial-failure-dashes-pfizers-growth-hopes-for-the-drug/
Eli Lilly and Gilead’s combination cuts COVID-19 recovery timeEli Lilly’s Olumiant (baricitinib) has a significant effect on recovery from COVID-19 when combined with Gilead Veklury (remdesivir), Share XEli Lilly and Gilead’s combination cuts COVID-19 recovery timehttps://pharmaphorum.com/news/eli-lilly-and-gileads-combination-cuts-covid-19-recovery-time/
Lilly asks FDA for emergency clearance for COVID-19 antibody therapyEli Lilly has asked the FDA for an Emergency Use Authorization for its COVID-19 antibody therapy, after announcing Share XLilly asks FDA for emergency clearance for COVID-19 antibody therapyhttps://pharmaphorum.com/news/lilly-asks-fda-for-emergency-clearance-for-covid-19-antibody-therapy/
BioNTech, Lilly shore up manufacturing capacity for their COVID-19 medsWith vaccines and drugs for COVID-19 now in late-stage development, companies are moving swiftly to lay down the Share XBioNTech, Lilly shore up manufacturing capacity for their COVID-19 medshttps://pharmaphorum.com/news/biontech-lilly-shore-up-manufacturing-capacity-for-their-covid-19-meds/
Lilly’s antibody therapy cuts hospitalisation rates in COVID-19Eli Lilly has followed up supportive data from its Olumiant in COVID-19 with results of a study showing Share XLilly’s antibody therapy cuts hospitalisation rates in COVID-19https://pharmaphorum.com/news/lilly-says-covid-19-antibody-therapy-cuts-hospitalisation-rates/
Trial backs Lilly’s Olumiant plus remdesivir as combo COVID-19 therapyAdding Eli Lilly’s rheumatoid arthritis drug Olumiant (baricitinib) and Gilead Sciences’ remdesivir reduces recovery time in COVID-19 patients Share XTrial backs Lilly’s Olumiant plus remdesivir as combo COVID-19 therapyhttps://pharmaphorum.com/news/trial-backs-lillys-olumiant-plus-remdesivir-as-combo-covid-19-therapy/
